Dishman Carbogen Amcis Limited
₹150.00▼ -1.18 (-0.78%)
DCAL·NSE·Healthcare
Market Cap
2347.83 Cr
PE Ratio
24.12
Volume
86,095
Day High - Low
151.50 - 148.81
52W High-Low
303.00 - 128.50
₹150.00▼ -1.18 (-0.78%)
Market Cap2347.83 Cr
PE Ratio24.12
Volume86,095
Day High - Low151.50 - 148.81
52W High-Low303.00 - 128.50
Dishman Carbogen Amcis Limited (DCAL): company summary
The company's annual revenue rose 8.1% to ₹2,932 crore, but the latest quarter saw revenue fall 4.3% year-on-year.
Dishman Carbogen Amcis Limited (DCAL) is a micro-cap Healthcare company valued at ₹2,348 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Dishman Carbogen Amcis Limited last traded at ₹150, modestly down 0.78% on the day.
- Recent developments
- On 2026-06-30, the company reported a net loss of ₹58 crore for the latest quarter, a reversal from a profit of ₹23 crore in the same quarter a year earlier. Promoter holding remained at 59.32%, while foreign institutional holding decreased by 0.59 percentage points, and domestic institutional holding increased by 0.44 percentage points.
- Financial performance
- The company's annual revenue rose 8.1% to ₹2,932 crore, but the latest quarter saw revenue fall 4.3% year-on-year. Net profit surged 3,148.3% annually to ₹97 crore, but the latest quarter ended with a net loss of ₹58 crore, marking a sharp reversal from a profit of ₹23 crore in the same quarter a year earlier. Margins improved significantly, with the net profit margin rising 3.2 percentage points to 3.3%, though returns remain low, with return on equity at 1.5%.
- Valuation multiples
- The stock trades at 24.1 times earnings, a discount to the Healthcare median of 32.0, 0.39 times book value.
- Things to watch
- The latest quarter ended with a net loss of ₹58 crore, reversing a profit of ₹23 crore in the same quarter a year earlier. The stock is 50.9% below its 52-week high, and the net profit margin, while up, is still low at 3.3%. Return on equity remains at 1.5%, indicating limited profitability relative to equity.
- Where it stands
- The company's annual net profit surged 3,148.3% to ₹97 crore, but the latest quarter ended with a net loss of ₹58 crore. Promoter holding remained at 59.32%, while foreign institutional holding decreased and domestic institutional holding increased. The stock is 50.9% below its 52-week high, and return on equity remains at 1.5%.
Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
5.1/10
Weak
Fair Value
Sign in to see
ROE
1.46%
Weak
P/E
24.12x
Fair
Debt / Equity
0.46
Moderate
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
Day₹148.81
₹151.50
52W₹128.50
₹303.00
DocStoX take
Supported by valuation (8.2) and growth (7.6), but held back by momentum (0.0). Valuation looks strong at 8.2, but that is offset by momentum at 0.0 and quality at 2.2. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence5.1
/10
Weak
Quality
Weak
ROE 1.5%
Valuation
Cheap
P/E 24.1×
Growth
Strong
Revenue +8.9% 5Y CAGR
Risk
Moderate
D/E 0.46
Momentum
Weak
12% of 52-week range
At a glance
Market Cap
₹2,348 Cr
52W High / Low
₹303 / ₹129
Dividend Yield
0.00%
Promoter Holding
59.32%
EPS (TTM)
₹6.22
Book Value
₹425.82
Key highlights
- Profit compounding 58% a year
- Loss-making in some of the last 5 years
- Quality is weak (2.2/10)
1 Positive4 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Dishman Carbogen Amcis Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Dishman Carbogen Amcis Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare Dishman Carbogen Amcis Limited with peers
Dishman Carbogen Amcis Limited vs Sun Pharmaceutical Industries LimitedDishman Carbogen Amcis Limited vs Divi's Laboratories LimitedDishman Carbogen Amcis Limited vs Torrent Pharmaceuticals LimitedDishman Carbogen Amcis Limited vs Apollo Hospitals Enterprise LimitedDishman Carbogen Amcis Limited vs Zydus Lifesciences LimitedDishman Carbogen Amcis Limited vs Laurus Labs Limited
Related tools & concepts
Value Dishman Carbogen Amcis Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing